Euroapi
Euroapi, a leading player in the pharmaceutical industry, is headquartered in France and operates across major regions in Europe and beyond. Founded in 2022, the company has quickly established itself as a key provider of active pharmaceutical ingredients (APIs) and advanced drug delivery systems. With a focus on innovation and sustainability, Euroapi offers a diverse range of products and services that cater to the evolving needs of the healthcare sector. Their commitment to quality and regulatory compliance sets them apart in a competitive market. Recognised for their expertise in complex APIs, Euroapi has achieved significant milestones, positioning itself as a trusted partner for pharmaceutical companies worldwide. As the industry continues to evolve, Euroapi remains dedicated to advancing healthcare solutions through cutting-edge technology and strategic collaborations.
DitchCarbon Score
How does Euroapi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Euroapi's score of 57 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Euroapi's reported carbon emissions
In 2024, Euroapi reported total carbon emissions of approximately 96,472,000 kg CO2e, a decrease from about 107,454,000 kg CO2e in 2023. The emissions data for 2022 indicates a total of 91,311,000 kg CO2e, which includes 61,250,000 kg CO2e from Scope 1 and 30,061,000 kg CO2e from Scope 2, alongside significant Scope 3 emissions of approximately 590,577,000 kg CO2e. Euroapi has set ambitious climate commitments, aiming for a 30% reduction in Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. Additionally, the company has established a more aggressive target of a 42% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2022 baseline. For Scope 3 emissions, Euroapi is targeting a 25% reduction by 2030. Looking further ahead, Euroapi has committed to achieving net-zero carbon emissions by 2050, with a goal of reducing total emissions (Scope 1, 2, and 3) by 90% compared to 2022 levels. These targets align with the Science Based Targets initiative (SBTi) and reflect Euroapi's commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 74,043,000 | 00,000,000 | 00,000,000 | - | - |
| Scope 2 | 40,003,000 | 00,000,000 | 00,000,000 | - | - |
| Scope 3 | - | 000,000,000 | 000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Euroapi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
